• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Eupraxia Pharmaceuticals Inc.

    11/14/25 9:10:51 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $EPRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    EUPRAXIA PHARMACEUTICALS INC.

    (Name of Issuer)


    Common Shares

    (Title of Class of Securities)


    29842P105

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    29842P105


    1Names of Reporting Persons

    Beutel, Goodman & Co Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ONTARIO, CANADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,899,519.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,058,899.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,058,899.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.0 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    EUPRAXIA PHARMACEUTICALS INC.
    (b)Address of issuer's principal executive offices:

    201-2067 CADBORO BAY RD., VICTORIA, BRITISH COLUMBIA, CANADA, V8R 5G4.
    Item 2. 
    (a)Name of person filing:

    Beutel, Goodman & Company Ltd.
    (b)Address or principal business office or, if none, residence:

    20 Eglinton Ave. W., Suite 2000 Toronto, Ontario, M4R 1K8, Canada
    (c)Citizenship:

    Canadian incorporated company
    (d)Title of class of securities:

    Common Shares
    (e)CUSIP No.:

    29842P105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4,058,899
    (b)Percent of class:

    8.0222  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    3,899,519

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    4,058,899

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Beutel, Goodman & Co Ltd.
     
    Signature:Michal Pomotov
    Name/Title:CCO & General Counsel
    Date:11/13/2025
    Get the next $EPRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EPRX

    DatePrice TargetRatingAnalyst
    7/24/2025$11.00Overweight
    Cantor Fitzgerald
    6/26/2025$12.00Buy
    H.C. Wainwright
    6/16/2025Speculative Buy
    Canaccord Genuity
    2/21/2025$12.00Buy
    Craig Hallum
    11/14/2024$9.00Buy
    Rodman & Renshaw
    More analyst ratings

    $EPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

    The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus far.In Cohort 6, a durable clinical symptom response was observed 52 weeks after a single administration of EP-104GI.All 3 patients in Cohort 6 maintained a clinical benefit and 2 out of 3 patients remain in clinical remission 52 weeks after treatment of EoE with EP-104GI.In combination with patients from Cohort 5, at 52 weeks, 4 out of 6 patients remain in clinical remission.At week 36, 67% of all patients in the trial that were measured at 36 weeks, were in clinical remission (Cohorts 5-7, n=9).O

    11/13/25 5:00:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

    Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Completed $80.5 million public offering supported by leading life science investors Cash runway to fund pipeline development and operations into the first half of 2028 VICTORIA, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet ne

    11/4/25 4:39:26 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

    Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients in Cohort 9 experienced the largest improvements in tissue health outcomes and eosinophil reduction observed to date.RESOLVE Safety Committee and members of the Eupraxia Clinical Advisory Board endorsed using the 8 mg dose per injection as the second dose for the ongoing Phase 2b portion of the RESOLVE study.Eupraxia intends to expand the EP-104GI development program, including increasing the number of patients in the Phase 2b portion of RESOLVE from 60 to at least 120 patients.Eupraxia intends t

    9/29/25 5:00:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Eupraxia Pharmaceuticals with a new price target

    Cantor Fitzgerald initiated coverage of Eupraxia Pharmaceuticals with a rating of Overweight and set a new price target of $11.00

    7/24/25 7:27:25 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    H.C. Wainwright initiated coverage on Eupraxia Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of Eupraxia Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    6/26/25 8:10:08 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Canaccord Genuity initiated coverage on Eupraxia Pharmaceuticals

    Canaccord Genuity initiated coverage of Eupraxia Pharmaceuticals with a rating of Speculative Buy

    6/16/25 11:20:22 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Eupraxia Pharmaceuticals Inc.

    SCHEDULE 13G/A - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/14/25 4:37:06 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SCHEDULE 13G filed by Eupraxia Pharmaceuticals Inc.

    SCHEDULE 13G - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/14/25 9:10:51 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

    6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

    11/13/25 5:00:06 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Eupraxia Pharmaceuticals Announces CFO Succession

    -  Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC, Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately. Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities. "Having previously served as Eupraxia's CFO

    2/18/25 7:00:00 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

    VICTORIA, BC, Oct. 31, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce that it has completed a non-brokered private placement of 8,905,638 Series 1 Preferred shares of the Company (the "Preferred Shares"), at a price of C$5.00 per Preferred Share for aggregate gross proceeds of C$44,528,190, by way of a non-brokered private placement (the "Private Placement").

    10/31/24 7:36:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $EPRX
    Financials

    Live finance-specific insights

    View All

    SEC Form SC 13G filed by Eupraxia Pharmaceuticals Inc.

    SC 13G - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/14/24 4:17:44 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SC 13D filed by Eupraxia Pharmaceuticals Inc.

    SC 13D - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/7/24 4:10:15 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

    Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026Announced positive data from Phase 1b/2a RESOLVE supporting the potential of EP-104GI to improve the standard of care for patients with Eosinophilic Esophagitis ("EoE")Additional data from cohorts 5–8 from Phase 1b/2a available in October 2025 VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with

    8/12/25 4:25:54 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

    Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quar

    5/6/25 6:00:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

    VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "During the fourth quarter of 2024, and again in the current quarter of 2025, we delivered compelling data from our Phase 1b/2a RESOLVE trial for EP-

    3/20/25 5:30:48 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care